FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322491039> ?p ?o ?g. }

• W4322491039 endingPage "109875" @default.
• W4322491039 startingPage "109875" @default.
• W4322491039 abstract "Ferroptosis is characterized by accumulation of lipid peroxides that leads to oxidative stress. In progressive rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) suffered from oxidative stress induced by generation of excess reactive oxygen species (ROS) and survived from elevated lipid oxidation. However the phenomenon of abnormal synovial fibroblasts proliferation under ferroptotic stress remain to be explained and the effects of this event on disease progression of RA need to be investigated.FLS from RA patients (RA-FLS) were stimulated with LPS as an inflammatory model in vitro, and simultaneously treated with ferroptosis inducer Erastin/RSL3 or inhibitor ferrostatin-1. Besides, small extracellular vesicles (sEV) from the supernatant of RA-FLS culture under Erastin/RSL3 management were isolated. The degree of ferroptosis in cells were evaluated by Lipid-ROS detection via flowcytometry and ferroptosis marker protein expression determined by western bloting. The expression of core component of ESCRT-III CHMP4A and CHMP5 was determined by western bloting, and knockdown of CHMP4A was further performed to detect the influence of ESCRT-III complex on ferroptosis as well as LPS/Erastin induced sEV (LPS/Erastin-sEV) releasing. Moreover, miR-433-3p level in the isolated sEV was evaluated by RT-qPCR and interaction of miR-433-3p with FOXO1/VEGF axis were evaluated. MiR-433-3p was overexpressed in synovial mesenchymal stem cells (SMSCs) via miR-433-3p mimics transfection. RA-FLS was co-cultured with human dermal microvascular endothelial cells (HDMECs). LPS/Erastin-sEV or sEV derived from miR-433-3p-overexpressing SMSCs (miR-433-3p-SMSCs-sEV) were added to the co-culture system, and supernatants from co-culture without sEV were given to HDMECs. Angiogenic activity of HDMECs were identified by transwell test and endothelial tube formation analysis. Erastin-sEV and miR-433-3p-SMSCs-sEV were also administrated in collagen-induced arthritis (CIA) mouse model respectively, and progression of arthritis were evaluated.Ferroptosis of RA-FLS was triggered by LPS/Erastin and accompanied with increased expression of ESCRT-III core components as well as elevated release of sEV from RA-FLS. HDMECs' migration and tube formation in vitro was significantly induced/suppressed by supernatants from co-culture under management of Erastin-sEV/miR-433-3p-SMSCs-sEV due to varied VEGF expression regulated by miR-433-3p targeting FOXO1. MiR-433-3p-SMSCs-sEV could inhibit the Erastin-sEV promoted VEGF expression and mitigated arthritis severity.Erastin-sEV could aggravate synovial angiogenesis and promote arthritis progression. Administration of miR-433-3p-SMSCs-sEV may be a potential novel therapeutic method as significant antagonism to Erastin-sEV for RA treatment." @default.
• W4322491039 created "2023-02-28" @default.
• W4322491039 creator A5020422198 @default.
• W4322491039 creator A5020425588 @default.
• W4322491039 creator A5039773171 @default.
• W4322491039 creator A5044078880 @default.
• W4322491039 creator A5045703368 @default.
• W4322491039 creator A5055471482 @default.
• W4322491039 creator A5059431543 @default.
• W4322491039 creator A5062788388 @default.
• W4322491039 creator A5077352796 @default.
• W4322491039 creator A5077488611 @default.
• W4322491039 creator A5080609965 @default.
• W4322491039 creator A5080820559 @default.
• W4322491039 date "2023-03-01" @default.
• W4322491039 modified "2023-10-10" @default.
• W4322491039 title "SMSCs-derived sEV overexpressing miR-433-3p inhibits angiogenesis induced by sEV released from synoviocytes under triggering of ferroptosis" @default.
• W4322491039 cites W1502551248 @default.
• W4322491039 cites W1997183854 @default.
• W4322491039 cites W2000097208 @default.
• W4322491039 cites W2038003822 @default.
• W4322491039 cites W2053957762 @default.
• W4322491039 cites W2114644968 @default.
• W4322491039 cites W2135110724 @default.
• W4322491039 cites W2163912530 @default.
• W4322491039 cites W2522630538 @default.
• W4322491039 cites W2604229956 @default.
• W4322491039 cites W2743555551 @default.
• W4322491039 cites W2745137260 @default.
• W4322491039 cites W2800857805 @default.
• W4322491039 cites W2894038927 @default.
• W4322491039 cites W2900507152 @default.
• W4322491039 cites W2954167484 @default.
• W4322491039 cites W2979937337 @default.
• W4322491039 cites W2985101511 @default.
• W4322491039 cites W2990717241 @default.
• W4322491039 cites W2999572345 @default.
• W4322491039 cites W3077764649 @default.
• W4322491039 cites W3080546447 @default.
• W4322491039 cites W3112044135 @default.
• W4322491039 cites W3123922203 @default.
• W4322491039 cites W3126536910 @default.
• W4322491039 cites W3161135646 @default.
• W4322491039 cites W3200562207 @default.
• W4322491039 cites W3208325566 @default.
• W4322491039 cites W3213200983 @default.
• W4322491039 cites W4200010317 @default.
• W4322491039 cites W4200030822 @default.
• W4322491039 cites W4205280123 @default.
• W4322491039 cites W4206979445 @default.
• W4322491039 cites W4220776161 @default.
• W4322491039 cites W4224279491 @default.
• W4322491039 cites W4226015327 @default.
• W4322491039 cites W4306816457 @default.
• W4322491039 doi "https://doi.org/10.1016/j.intimp.2023.109875" @default.
• W4322491039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37501360" @default.
• W4322491039 hasPublicationYear "2023" @default.
• W4322491039 type Work @default.
• W4322491039 citedByCount "0" @default.
• W4322491039 crossrefType "journal-article" @default.
• W4322491039 hasAuthorship W4322491039A5020422198 @default.
• W4322491039 hasAuthorship W4322491039A5020425588 @default.
• W4322491039 hasAuthorship W4322491039A5039773171 @default.
• W4322491039 hasAuthorship W4322491039A5044078880 @default.
• W4322491039 hasAuthorship W4322491039A5045703368 @default.
• W4322491039 hasAuthorship W4322491039A5055471482 @default.
• W4322491039 hasAuthorship W4322491039A5059431543 @default.
• W4322491039 hasAuthorship W4322491039A5062788388 @default.
• W4322491039 hasAuthorship W4322491039A5077352796 @default.
• W4322491039 hasAuthorship W4322491039A5077488611 @default.
• W4322491039 hasAuthorship W4322491039A5080609965 @default.
• W4322491039 hasAuthorship W4322491039A5080820559 @default.
• W4322491039 hasConcept C104317684 @default.
• W4322491039 hasConcept C153911025 @default.
• W4322491039 hasConcept C173396325 @default.
• W4322491039 hasConcept C185592680 @default.
• W4322491039 hasConcept C190283241 @default.
• W4322491039 hasConcept C202751555 @default.
• W4322491039 hasConcept C2776151105 @default.
• W4322491039 hasConcept C2780381497 @default.
• W4322491039 hasConcept C2780394083 @default.
• W4322491039 hasConcept C502942594 @default.
• W4322491039 hasConcept C54009773 @default.
• W4322491039 hasConcept C55493867 @default.
• W4322491039 hasConcept C86803240 @default.
• W4322491039 hasConcept C95444343 @default.
• W4322491039 hasConceptScore W4322491039C104317684 @default.
• W4322491039 hasConceptScore W4322491039C153911025 @default.
• W4322491039 hasConceptScore W4322491039C173396325 @default.
• W4322491039 hasConceptScore W4322491039C185592680 @default.
• W4322491039 hasConceptScore W4322491039C190283241 @default.
• W4322491039 hasConceptScore W4322491039C202751555 @default.
• W4322491039 hasConceptScore W4322491039C2776151105 @default.
• W4322491039 hasConceptScore W4322491039C2780381497 @default.
• W4322491039 hasConceptScore W4322491039C2780394083 @default.
• W4322491039 hasConceptScore W4322491039C502942594 @default.
• W4322491039 hasConceptScore W4322491039C54009773 @default.
• W4322491039 hasConceptScore W4322491039C55493867 @default.

• next